Journal of Inherited Metabolic Disease

, Volume 28, Issue 1, pp 89–93

Screening for Menkes disease using the urine HVA/VMA ratio

Article

Summary

Menkes disease is a disorder of copper transport that results in early death. Early therapy with parenteral copper-histidine has been shown to markedly improve outcomes. However, early diagnosis is difficult because patients are asymptomatic in early infancy. In Menkes disease, impaired activity of dopamine β-hydroxylase, a copper-dependent enzyme, leads to increased urine ratios of homovanillic acid/vanillylmandelic acid (HVA/VMA). Urine HVA/VMA ratios ranged from 4.1 to 69.7 among 15 patients with Menkes disease, whereas only 0.18% of controls had ratios greater than 4.0. Thus, the urine HVA/VMA ratio is a useful screening method for Menkes disease.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Chelly J, Tumer Z, Tonnesen T, et al (1993) Isolation of a candidate gene for Menkes disease that encodes a potential heavy metal binding protein. Nature Genetics 3: 14–19.CrossRefPubMedGoogle Scholar
  2. Christodoulou J, Danks DM, Sarkar B, et al (1998) Early treatment of Menkes disease with parenteral copper-histidine: long-term follow-up of four treated patients. Am J Med Genet 76: 154–164.CrossRefPubMedGoogle Scholar
  3. Culotta VC, Gitlin JD (2001) Disorders of copper transport. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc. eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn, vol. 2. New York: McGraw-Hill, 3105–3126.Google Scholar
  4. Danks DM, Campbell PE, Stevens BJ, Mayne V, Cartwright E (1972) Menkes’ kinky hair syndrome: an inherited defect in copper absorption with widespread effects. Pediatrics 50: 188–201.PubMedGoogle Scholar
  5. Hanai J, Kawai T, Sato Y, Takasugi N, Nishi M, Takeda T (1987) Simple liquid-chromatographic measurement of vanillylmandelic acid and homovanillic acid in urine on filter paper for mass screening of neuroblastoma in infants. Clin Chem 33: 2043–2046.PubMedGoogle Scholar
  6. Kaler SG (1994) Menkes disease. Adv Pediatr 41: 263–304.PubMedGoogle Scholar
  7. Kaler SG, Gahl WA, Berry SA, Holmes CS, Goldstein DS (1993a) Predictive value of plasma catecholamine levels in neonatal detection of Menkes disease. J Inherit Metab Dis 16: 907–908.CrossRefPubMedGoogle Scholar
  8. Kaler SG, Goldstein DS, Holmes CS, Salerno JA, Gahl WA (1993b) Plasma and cerebrospinal fluid neurochemical pattern in Menkes disease. Ann Neurol 33: 171–175.CrossRefPubMedGoogle Scholar
  9. Mercer JFB, Livingston J, Hall B, et al (1993) Isolation of a partial candidate gene for Menkes disease by positional cloning. Nature Genetics 3: 20–25.CrossRefPubMedGoogle Scholar
  10. Sarkar B, Lingertat-Walsh K, Clarke JTR (1993) Copper-histidine therapy for Menkes disease. J Pediatr 123: 828–830.PubMedGoogle Scholar
  11. Sherwood G, Sarkar B, Kortsak AS (1989) Copper histidinate therapy in Menkes’ disease: prevention of progressive neurodegeneration. J Inherit Metab Dis 12(supplement 2): 393–396.PubMedGoogle Scholar
  12. Tonnesen T, Kleijer WL, Horn N (1991) Incidence of Menkes disease. Hum Genet 86: 408–410.PubMedGoogle Scholar
  13. Tuchman M, Lemieux B, Auray-Blais C, et al (1990) Screening for neuroblastoma at 3 weeks of age: methods and preliminary results from the Quebec Neuroblastoma Screening Project. Pediatrics 86: 765–773.PubMedGoogle Scholar
  14. Vulpe C, Levinson B, Whitney S, Packman S, Gitschier J (1993) Isolation of a candidate gene for Menkes disease and evidence that it encodes a copper-transporting ATPase. Nature Genetics 3: 7–13.CrossRefPubMedGoogle Scholar

Copyright information

© SSIEM and Springer 2005

Authors and Affiliations

  1. 1.Department of Pediatrics, Faculty of MedicineSaga UniversitySagaJapan
  2. 2.The Chemo-Sero-Therapeutic Research InstituteClinical Laboratory CenterKumamoto
  3. 3.Department of PediatricsTokyo University School of MedicineTokyoJapan

Personalised recommendations